Document Detail


Phase I trials of targeted anticancer drugs: a need to refocus.
MedLine Citation:
PMID:  23197020     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
As cancer therapy progresses through the development of molecularly targeted drugs, the focus of Phase I trials needs to shift towards investigating end points that could guide more effective trial design, dosing and choice of tumour setting for Phase II studies.
Authors:
Ernest C Borden; Afshin Dowlati
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Nature reviews. Drug discovery     Volume:  11     ISSN:  1474-1784     ISO Abbreviation:  Nat Rev Drug Discov     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-30     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101124171     Medline TA:  Nat Rev Drug Discov     Country:  England    
Other Details:
Languages:  eng     Pagination:  889-90     Citation Subset:  IM    
Affiliation:
Case Comprehensive Cancer Center, Taussig Cancer Institute R40, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Reflections on my Family History, my Youth, and my Professional Career.
Next Document:  Reducing safety-related drug attrition: the use of in vitro pharmacological profiling.